Nevertheless, it is worth noting that JAK2V617F mutation is not the only regulatory mechanism responsible for the low expression of GADD45g in MPNs, and that GADD45g reduction only partially mediates the tumor-promoting activities of JAK2V617F mutation in a xenograft model of MPN. Here, GADD45G is linked to myeloproliferative disorder.